AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 11686825 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.09% chlorhexidine + 1% PVP
Number of subjects: 66
Study 11686825 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.09% chlorhexidine + 3% PVP
Number of subjects: 66
Study 11686825 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.09% chlorhexidine + 5% PVP
Number of subjects: 66
Study 11686825 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.09% chlorhexidine + 7% PVP
Number of subjects: 66
Study 11686825 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2% chlorhexidine
Number of subjects: 66
Study 11686825 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2% chlorhexidine + 10% PVP
Number of subjects: 66
Study 11686825 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study 11686825 — intervention group
Group type: EXPERIMENTAL
Intervention: Essential oil product
Number of subjects: 66
Study 9459398 — intervention group
Group type: EXPERIMENTAL
Intervention: i.v. ceftriaxone
Number of subjects: 38
Study 9459398 — intervention group
Group type: EXPERIMENTAL
Intervention: oral cefixime
Number of subjects: 38
Study 9459398 — intervention group
Group type: COMPARATOR
Intervention: Baseline serum IL‐6 values >400 pg/ml
Number of subjects: 38
Study 7948058 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg yohimbine
Number of subjects: 20
Study 7948058 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 3215290 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5, 3.0 and 6.0 megaunits (MU) of interferon A per day
Number of subjects: 412
Study 3215290 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 412
Study 30427997 — intervention group
Group type: EXPERIMENTAL
Intervention: NT-proBNP
Number of subjects: 17095
Study 30427997 — intervention group
Group type: EXPERIMENTAL
Intervention: GDF-15
Number of subjects: 17095
Study 30427997 — intervention group
Group type: EXPERIMENTAL
Intervention: C-reactive protein, GDF-15, cystatin-C
Number of subjects: 17095
Study 27323346 — intervention group
Group type: EXPERIMENTAL
Intervention: RT + cetuximab
Number of subjects: 181
Study 27323346 — intervention group
Group type: COMPARATOR
Intervention: RT alone
Number of subjects: 181
Study 26216033 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac resynchronization therapy with defibrillator (CRT-D)
Number of subjects: 1263
Study 23743804 — intervention group
Group type: EXPERIMENTAL
Intervention: STITCH2-care (simplified treatment algorithm featuring single-pill combinations)
Number of subjects: 1750
Study 23743804 — intervention group
Group type: COMPARATOR
Intervention: Guidelines-care (following current Canadian guidelines)
Number of subjects: 1750
Study 23743804 — intervention group
Group type: EXPERIMENTAL
Intervention: STITCH2-care
Number of subjects: 1750
Study 20883456 — intervention group
Group type: EXPERIMENTAL
Intervention: SQ-standardized HDM SCIT
Number of subjects: 54
Study 19068113 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed-loop control based on fuzzy logic
Number of subjects: 39
Study 19068113 — intervention group
Group type: COMPARATOR
Intervention: Control group (clinician's discretion)
Number of subjects: 39
Study 16425137 — intervention group
Group type: EXPERIMENTAL
Intervention: rA2cp Delta NS2 (10^7.0 pfu)
Number of subjects: 0
Study 16425137 — intervention group
Group type: EXPERIMENTAL
Intervention: rA2cp248/404 Delta NS2
Number of subjects: 0
Study 16425137 — intervention group
Group type: EXPERIMENTAL
Intervention: rA2cp530/1009 Delta NS2
Number of subjects: 0
Study 14596683 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoximone (1.5 mg/kg)
Number of subjects: 26
Study 14596683 — intervention group
Group type: COMPARATOR
Intervention: Dobutamine (5 and 10 micrograms/kg/min)
Number of subjects: 26
Study 10852450 — intervention group
Group type: EXPERIMENTAL
Intervention: Endotoxin (2.0-3.0 ng/kg) in E2-replaced women
Number of subjects: 10
Study 10852450 — intervention group
Group type: EXPERIMENTAL
Intervention: ACTH infusion (Cortrosyn, 50 microg/h) in E2-replaced women
Number of subjects: 10
Study 10852450 — intervention group
Group type: COMPARATOR
Intervention: Endotoxin (2.0-3.0 ng/kg) in unreplaced women
Number of subjects: 10
Study 9356764 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine supplementation (20 g/day plus 4 g/day glucose)
Number of subjects: 80
Study 9356764 — intervention group
Group type: COMPARATOR
Intervention: Placebo (24 g/day glucose)
Number of subjects: 80
Study 1539814 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrical single twitch stimulation at the spinal nerve dermatome one segment rostrad of the proximal extent of sensory paralysis (Group A)
Number of subjects: 18
Study 1539814 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrical twitch stimulation at the anterior crural region (Group B)
Number of subjects: 18
Study 1539814 — intervention group
Group type: COMPARATOR
Intervention: No stimulation (Control Group C)
Number of subjects: 18
Study 3882125 — intervention group
Group type: EXPERIMENTAL
Intervention: Isotretinoin (40 mg daily for 2 months)
Number of subjects: 16
Study 3882125 — intervention group
Group type: EXPERIMENTAL
Intervention: Etretinate (50 mg daily for 2 months)
Number of subjects: 16
Study 31144165 — intervention group
Group type: EXPERIMENTAL
Intervention: Automatic position-adaptive stimulation
Number of subjects: 18
Study 31144165 — intervention group
Group type: COMPARATOR
Intervention: Manual stimulation
Number of subjects: 18
Study 28991039 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-load resistance exercise (60%-65% 1-repetition maximum, two sets of 15-20 repetitions)
Number of subjects: 21
Study 28991039 — intervention group
Group type: EXPERIMENTAL
Intervention: Heavy-load resistance exercise (85%-90% 1-repetition maximum, three sets of 5-8 repetitions)
Number of subjects: 21
Study 27247055 — intervention group
Group type: EXPERIMENTAL
Intervention: 16Gy boost to the tumour bed
Number of subjects: 864
Study 27247055 — intervention group
Group type: COMPARATOR
Intervention: 26Gy boost to the tumour bed
Number of subjects: 864
Study 27247055 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions (16Gy and 26Gy)
Number of subjects: 864
Study 26475663 — intervention group
Group type: COMPARATOR
Intervention: Telehealth service delivery model
Number of subjects: 0
Study 26475663 — intervention group
Group type: COMPARATOR
Intervention: Traditional full assessment
Number of subjects: 0
Study 26475663 — intervention group
Group type: COMPARATOR
Intervention: Telehealth risk assessment and screening
Number of subjects: 0
Study 22423669 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavior modification program (nutritional education, modifying dietary habits, exercise programs, nutritional facts for parents, exercises 3 days a week)
Number of subjects: 152
Study 22423669 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavior modification program
Number of subjects: 152
Study 20357588 — intervention group
Group type: COMPARATOR
Intervention: Ponseti technique
Number of subjects: 33
Study 20357588 — intervention group
Group type: EXPERIMENTAL
Intervention: French physical therapy (PT)
Number of subjects: 33
Study 20357588 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined group (moderate and severe clubfeet)
Number of subjects: 33
Study 18564079 — intervention group
Group type: EXPERIMENTAL
Intervention: Preterm-targeted screening programme
Number of subjects: 202
Study 18564079 — intervention group
Group type: COMPARATOR
Intervention: NHMRC universal child health screening programme
Number of subjects: 202
Study 15573366 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally invasive parathyroidectomy (MIP) under local anaesthesia, n = 25
Number of subjects: 50
Study 15573366 — intervention group
Group type: COMPARATOR
Intervention: Conventional bilateral cervical exploration (BCE) under general anaesthesia, n = 25
Number of subjects: 50
Study 12454831 — intervention group
Group type: EXPERIMENTAL
Intervention: PAC7 (pantoprazole 40 mg, amoxicillin 1000 mg, clarithromycin 500 mg, all twice daily for 7 days)
Number of subjects: 405
Study 12454831 — intervention group
Group type: EXPERIMENTAL
Intervention: PBTM7 (pantoprazole 40 mg twice daily, bismuth subcitrate 108 mg, tetracycline 500 mg, both 4 times daily, metronidazole 200 mg 3 times daily and 400 mg at night for 7 days)
Number of subjects: 405
Study 12454831 — intervention group
Group type: COMPARATOR
Intervention: BTM14 (bismuth subcitrate 108 mg and tetracycline 500 mg, both 4 times daily, metronidazole 200 mg 3 times daily and 400 mg at night for 14 days)
Number of subjects: 405
Study 12454831 — intervention group
Group type: EXPERIMENTAL
Intervention: PAC7
Number of subjects: 405
Study 12454831 — intervention group
Group type: EXPERIMENTAL
Intervention: PBTM7
Number of subjects: 405
Study 12454831 — intervention group
Group type: COMPARATOR
Intervention: BTM14
Number of subjects: 405
Study 10037123 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma from whole-blood preparation, adjusted to 10 x 10(9) platelets per mL
Number of subjects: 19
Study 10037123 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelets collected by apheresis, adjusted to 20 x 10(9) platelets per mL
Number of subjects: 19
Study 8748394 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxazepam 20 mg
Number of subjects: 18
Study 8748394 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxazepam 40 mg
Number of subjects: 18
Study 8748394 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 8748394 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxazepam (both doses)
Number of subjects: 18
Study 8748394 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxazepam
Number of subjects: 18
Study 8748394 — intervention group
Group type: EXPERIMENTAL
Intervention: Time-on-task
Number of subjects: 18
Study 1777788 — intervention group
Group type: EXPERIMENTAL
Intervention: Low intensity arm exercise
Number of subjects: 10
Study 1777788 — intervention group
Group type: EXPERIMENTAL
Intervention: Low intensity leg exercise
Number of subjects: 10
Study 1777788 — intervention group
Group type: COMPARATOR
Intervention: Supine rest
Number of subjects: 10
Study 6337364 — intervention group
Group type: EXPERIMENTAL
Intervention: Glutathione bicarbonate Ringer's (GBR) intraocular irrigation fluid
Number of subjects: 80
Study 6337364 — intervention group
Group type: COMPARATOR
Intervention: Ringer's solution
Number of subjects: 80
Study 31733780 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined exercise group (sensorimotor training + traditional exercises)
Number of subjects: 53
Study 31733780 — intervention group
Group type: COMPARATOR
Intervention: Traditional exercise group
Number of subjects: 53
Study 29683560 — intervention group
Group type: EXPERIMENTAL
Intervention: Hands-on ultrasound training
Number of subjects: 43
Study 29683560 — intervention group
Group type: COMPARATOR
Intervention: No hands-on training
Number of subjects: 43
Study 26843092 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 g CLA (75 % c9,t11‐CLA, 87 % purity)
Number of subjects: 29
Study 26843092 — intervention group
Group type: COMPARATOR
Intervention: Placebo (safflower oil)
Number of subjects: 29
Study 23306948 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma rich in growth factors (PRGF)
Number of subjects: 20
Study 23306948 — intervention group
Group type: COMPARATOR
Intervention: Control group (no PRGF)
Number of subjects: 20
Study 22304357 — intervention group
Group type: EXPERIMENTAL
Intervention: Trombopol 75 mg
Number of subjects: 30
Study 22304357 — intervention group
Group type: COMPARATOR
Intervention: Aspirin cardio 100 mg
Number of subjects: 30
Study 20511163 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegfilgrastim 6 mg on day 1 (arm A)
Number of subjects: 101
Study 20511163 — intervention group
Group type: COMPARATOR
Intervention: Weight-based, dose-adjusted filgrastim beginning on day 1 (arm B)
Number of subjects: 101
Study 17009304 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3 M potassium chloride (KCl)
Number of subjects: 23
Study 17009304 — intervention group
Group type: COMPARATOR
Intervention: 0.9% normal saline (NS)
Number of subjects: 23
Study 17110817 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine 300 mg/d
Number of subjects: 509
Study 17110817 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine 600 mg/d
Number of subjects: 509
Study 17110817 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine (both doses)
Number of subjects: 509
Study 17110817 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 509
Study 15279057 — intervention group
Group type: EXPERIMENTAL
Intervention: Real rTMS
Number of subjects: 22
Study 15279057 — intervention group
Group type: COMPARATOR
Intervention: Sham rTMS (Control)
Number of subjects: 22
Study 11077496 — intervention group
Group type: EXPERIMENTAL
Intervention: ppWhipple
Number of subjects: 93
Study 11077496 — intervention group
Group type: COMPARATOR
Intervention: cWhipple
Number of subjects: 93
Study 8739501 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% sodium hyaluronate eyedrops
Number of subjects: 12
Study 8739501 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3% sodium hyaluronate eyedrops
Number of subjects: 12
Study 8739501 — intervention group
Group type: COMPARATOR
Intervention: 0% sodium hyaluronate eyedrops
Number of subjects: 12
Study 8739501 — intervention group
Group type: COMPARATOR
Intervention: 0.05% sodium hyaluronate eyedrops
Number of subjects: 12
Study 1404632 — intervention group
Group type: EXPERIMENTAL
Intervention: Papaverine plus prostaglandin E1
Number of subjects: 7
Study 1404632 — intervention group
Group type: EXPERIMENTAL
Intervention: Papaverine plus phentolamine plus prostaglandin E1
Number of subjects: 7
Study 1404632 — intervention group
Group type: COMPARATOR
Intervention: Papaverine plus phentolamine
Number of subjects: 7
Study 2408846 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine (225 micrograms)
Number of subjects: 6
Study 2408846 — intervention group
Group type: EXPERIMENTAL
Intervention: Yohimbine (15 mg)
Number of subjects: 6
Study 2408846 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine + Yohimbine
Number of subjects: 6
Study 2408846 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 30113524 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised exercise intervention
Number of subjects: 1514
Study 30113524 — intervention group
Group type: COMPARATOR
Intervention: National guidelines for physical activity (Control)
Number of subjects: 1514
Study 27956057 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil 0.05μg/kg/min (group R1)
Number of subjects: 60
Study 27956057 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil 0.1μg/kg/min (group R2)
Number of subjects: 60
Study 27956057 — intervention group
Group type: COMPARATOR
Intervention: High levels of anxiety
Number of subjects: 60
Study 25586812 — intervention group
Group type: EXPERIMENTAL
Intervention: Home telemonitoring with usual care
Number of subjects: 110
Study 25586812 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 110
Study 23499726 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide-evorolimus combination therapy (everolimus 2.5 mg daily + octreotide 40 mg every 4 weeks)
Number of subjects: 44
Study 23499726 — intervention group
Group type: COMPARATOR
Intervention: Octreotide monotherapy (octreotide 40 mg every 4 weeks)
Number of subjects: 44
Study 21459996 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication
Number of subjects: 206
Study 21459996 — intervention group
Group type: EXPERIMENTAL
Intervention: Counseling or psychotherapy
Number of subjects: 206
Study 18095028 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical sucralfate cream
Number of subjects: 116
Study 18095028 — intervention group
Group type: COMPARATOR
Intervention: Placebo cream
Number of subjects: 116
Study 16426710 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyphenol supplement (2.3g polyphenols/trial)
Number of subjects: 30
Study 16426710 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 14594754 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavior therapy
Number of subjects: 33
Study 14594754 — intervention group
Group type: COMPARATOR
Intervention: Nutritional counseling
Number of subjects: 33
Study 11069364 — intervention group
Group type: EXPERIMENTAL
Intervention: recombinant interferon gamma‐1b (60 microg/m2) subcutaneously once every 7 days until disease progression
Number of subjects: 197
Study 11069364 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 197
Study 8616014 — intervention group
Group type: EXPERIMENTAL
Intervention: FLAC + PIXY321
Number of subjects: 0
Study 8616014 — intervention group
Group type: EXPERIMENTAL
Intervention: FLAC + GM‐CSF
Number of subjects: 0
Study 8616014 — intervention group
Group type: COMPARATOR
Intervention: FLAC without cytokine
Number of subjects: 0
Study 8616014 — intervention group
Group type: EXPERIMENTAL
Intervention: All three treatment arms (FLAC + PIXY321, FLAC + GM‐CSF, FLAC without cytokine)
Number of subjects: 0
Study 8616014 — intervention group
Group type: EXPERIMENTAL
Intervention: FLAC
Number of subjects: 0
Study 1330271 — intervention group
Group type: EXPERIMENTAL
Intervention: Afternoon testing (5.0 W.kg‐1 for women, 6.0 W.kg‐1 for men)
Number of subjects: 14
Study 1330271 — intervention group
Group type: COMPARATOR
Intervention: Morning testing (5.0 W.kg‐1 for women, 6.0 W.kg‐1 for men)
Number of subjects: 14
Study 1330271 — intervention group
Group type: EXPERIMENTAL
Intervention: Afternoon testing
Number of subjects: 14
Study 3965024 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified fat diet (rich in linoleic acid)
Number of subjects: 149
Study 3965024 — intervention group
Group type: COMPARATOR
Intervention: Low carbohydrate diet
Number of subjects: 149
Study 3965024 — intervention group
Group type: EXPERIMENTAL
Intervention: Low linoleic acid levels
Number of subjects: 149
Study 3965024 — intervention group
Group type: EXPERIMENTAL
Intervention: High linoleic acid levels
Number of subjects: 149
Study 30626414 — intervention group
Group type: EXPERIMENTAL
Intervention: TRT + EMDR
Number of subjects: 166
Study 30626414 — intervention group
Group type: COMPARATOR
Intervention: TRT + CBT
Number of subjects: 166
Study 30249826 — intervention group
Group type: EXPERIMENTAL
Intervention: AT‐TORBI plate haptic toric IOL
Number of subjects: 42
Study 30249826 — intervention group
Group type: COMPARATOR
Intervention: AcrySof loop haptic toric IOL
Number of subjects: 42
Study 26836730 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetazolamide (500-1000 mg, twice daily)
Number of subjects: 382
Study 26836730 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 382
Study 25181492 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily breakfast consumption
Number of subjects: 4116
Study 25181492 — intervention group
Group type: EXPERIMENTAL
Intervention: High fibre cereal breakfast
Number of subjects: 4116
Study 25181492 — intervention group
Group type: COMPARATOR
Intervention: Not usually having breakfast
Number of subjects: 4116
Study 22112608 — intervention group
Group type: EXPERIMENTAL
Intervention: Aflibercept 4mg/kg every 2 weeks
Number of subjects: 16
Study 19453849 — intervention group
Group type: EXPERIMENTAL
Intervention: Particulate demineralized bone matrix (DBM)
Number of subjects: 25
Study 19453849 — intervention group
Group type: EXPERIMENTAL
Intervention: Putty demineralized bone matrix (DBM)
Number of subjects: 25
Study 19453849 — intervention group
Group type: COMPARATOR
Intervention: Open flap debridement (OFD)
Number of subjects: 25
Study 17215188 — intervention group
Group type: EXPERIMENTAL
Intervention: NaFeEDTA (20 mg Fe/kg)
Number of subjects: 400
Study 17215188 — intervention group
Group type: EXPERIMENTAL
Intervention: FeSO4 (30 mg Fe/kg)
Number of subjects: 400
Study 17215188 — intervention group
Group type: EXPERIMENTAL
Intervention: Elemental iron (60 mg Fe/kg)
Number of subjects: 400
Study 17215188 — intervention group
Group type: COMPARATOR
Intervention: Control group (no added iron)
Number of subjects: 400
Study 15285975 — intervention group
Group type: EXPERIMENTAL
Intervention: Telepsychiatry
Number of subjects: 119
Study 15285975 — intervention group
Group type: COMPARATOR
Intervention: In-person treatment
Number of subjects: 119
Study 11730828 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined hormone replacement therapy (2 mg of estradiol combined with 1 mg of norethisterone acetate daily)
Number of subjects: 74
Study 11730828 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 74
Study 9143862 — intervention group
Group type: EXPERIMENTAL
Intervention: Celiprolol (2 times 0.5 mg.kg‐1)
Number of subjects: 5
Study 9143862 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 5
Study 8233423 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine
Number of subjects: 0
Study 8233423 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 0
Study 3440102 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenosine after placebo
Number of subjects: 10
Study 3440102 — intervention group
Group type: COMPARATOR
Intervention: Caffeine
Number of subjects: 10
Study 3440102 — intervention group
Group type: COMPARATOR
Intervention: Enprofylline
Number of subjects: 10
Study 31939259 — intervention group
Group type: EXPERIMENTAL
Intervention: Freshwater snails identified and their geographical distribution determined using multistage sampling and ArcGIS software.
Number of subjects: 4400
Study 28189500 — intervention group
Group type: EXPERIMENTAL
Intervention: Shaping Healthy Choices Program (SHCP)
Number of subjects: 409
Study 28189500 — intervention group
Group type: COMPARATOR
Intervention: Control schools
Number of subjects: 409
Study 26752189 — intervention group
Group type: EXPERIMENTAL
Intervention: Mericitabine added to PI plus PegIFN alfa‐2a/RBV therapy
Number of subjects: 0
Study 26752189 — intervention group
Group type: COMPARATOR
Intervention: Placebo control arms
Number of subjects: 0
Study 26752189 — intervention group
Group type: EXPERIMENTAL
Intervention: Longer treatment with mericitabine (24 weeks)
Number of subjects: 0
Study 26752189 — intervention group
Group type: EXPERIMENTAL
Intervention: Telaprevir-containing regimens
Number of subjects: 0
Study 26752189 — intervention group
Group type: EXPERIMENTAL
Intervention: Regimens that included 48 weeks of PegIFN alfa‐2a/RBV therapy
Number of subjects: 0
Study 26752189 — intervention group
Group type: EXPERIMENTAL
Intervention: Mericitabine
Number of subjects: 0
Study 25141831 — intervention group
Group type: EXPERIMENTAL
Intervention: i-gel
Number of subjects: 100
Study 25141831 — intervention group
Group type: COMPARATOR
Intervention: LMA-Supreme
Number of subjects: 100
Study 21805567 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 Fr catheters with ACI
Number of subjects: 164
Study 21805567 — intervention group
Group type: COMPARATOR
Intervention: 6 Fr catheters with manual injection
Number of subjects: 164